Skip to main content

Advertisement

SpringerLink
Log in

New Agents for Acute Treatment of Migraine: CGRP Receptor Antagonists, iNOS Inhibitors

  • Headache (JR Couch, Section Editor)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

The treatment of migraine was advanced dramatically with the introduction of triptans in the early 1990s. Despite the substantial improvement in the quality of life that triptans have brought to many migraineurs, a substantial cohort of patients remain highly disabled by attacks and need new therapeutic approaches, which ideally should be quick-acting, have no vasoconstrictor activity, and have a longer duration of action and be better tolerated than current therapies. The calcitonin gene-related peptide (CGRP) receptor antagonists (gepants)—olcegepant (BIBN 4096 BS), telcagepant (MK-0974), MK3207, and BI 44370 TA—are effective in treating acute migraine. They have no vasoconstrictive properties, fewer adverse effects, and may act longer than triptans. Their development has been complicated by liver toxicity issues when used as preventives. Results from studies with BI 44370 TA do not support broad concern about a class effect, and further studies are ongoing in this respect. Many experimental studies and clinical trials suggest that nitric oxide may have a role in the pathophysiology of migraine. Therefore, the inhibition of nitric oxide synthase (NOS) for the acute or prophylactic treatment of migraine offered a feasible approach; as inducible NOS (iNOS) is involved in several pain states, such as inflammatory pain, it appeared to be an attractive target. However, despite high selectivity and potency, the iNOS inhibitor GW274150 was not effective for acute treatment or prophylaxis of migraine, suggesting that iNOS is very unlikely to be a promising target.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Stovner L, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193–210.

    Article  PubMed  Google Scholar 

  2. Menken M, Munsat TL, Toole JF. The global burden of disease study: implications for neurology. Arch Neurol. 2000;57(3):418–20.

    Article  PubMed  CAS  Google Scholar 

  3. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population-a prevalence study. J Clin Epidemiol. 1991;44(11):1147–57.

    Article  PubMed  CAS  Google Scholar 

  4. Silberstein SD, Lipton RB. Headache epidemiology. Emphasis on migraine. Neurol Clin. 1996;14(2):421–34.

    Article  PubMed  CAS  Google Scholar 

  5. Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache. 1998;38(7):497–506.

    Article  PubMed  CAS  Google Scholar 

  6. Lipton RB, Scher AI, Kolodner K, et al. Migraine in the United States: epidemiology and patterns of health care use. Neurology. 2002;58(6):885–94.

    PubMed  CAS  Google Scholar 

  7. Robbins MS, Lipton RB. The epidemiology of primary headache disorders. Semin Neurol. 2010;30(2):107–19.

    Article  PubMed  Google Scholar 

  8. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358(9294):1668–75.

    Article  PubMed  CAS  Google Scholar 

  9. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6(10):573–82.

    Article  PubMed  CAS  Google Scholar 

  10. Goadsby PJ. The vascular theory of migraine - a great story wrecked by the facts. Brain. 2009;132(Pt 1):6–7.

    PubMed  Google Scholar 

  11. Diener HC. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG Study Group. Cephalalgia. 1999;19(6):581–8.

    Article  PubMed  CAS  Google Scholar 

  12. Limmroth V, May A, Diener H. Lysine-acetylsalicylic acid in acute migraine attacks. Eur Neurol. 1999;41(2):88–93.

    Article  PubMed  CAS  Google Scholar 

  13. Weatherall MW, Telzerow AJ, Cittadini E, et al. Intravenous aspirin (lysine acetylsalicylate) in the inpatient management of headache. Neurology 2010;75(12):1098–1103.

    Article  PubMed  CAS  Google Scholar 

  14. Diener HC, Barbanti P, Dahlof C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 2011;31(5):573–584.

    Article  PubMed  Google Scholar 

  15. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008;372(9656):2115–23.

    Article  PubMed  CAS  Google Scholar 

  16. Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008;70(16):1304–12.

    Article  PubMed  CAS  Google Scholar 

  17. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350(11):1104–10.

    Article  PubMed  CAS  Google Scholar 

  18. Nelson DL, Phebus LA, Johnson KW, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia. 2010;30(10):1159–69.

    Article  PubMed  Google Scholar 

  19. Pilgrim AJ, Dussault B, Rupniak NMJ, et al. COL-144, an orally bioavailable selective 5-HT1F receptor agonist for acute migraine therapy. Cephalalgia. 2009;29:24–5.

    Google Scholar 

  20. Olesen J. 5-Hydroxyptryptamine 1F (5-HT1F) receptor agonism. A possible new treatment principle for acute migraine attacks. Cephalalgia. 2010;30(10):1157–8.

    Article  PubMed  Google Scholar 

  21. Ferrari MD, Farkkila M, Reuter U, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomised proof-of-concept trial. Cephalalgia 2010;30(10):1170–1178.

    Article  PubMed  Google Scholar 

  22. Limmroth V, May A, Auerbach P, et al. Changes in cerebral blood flow velocity after treatment with sumatriptan or placebo and implications for the pathophysiology of migraine. J Neurol Sci. 1996;138(1–2):60–5.

    Article  PubMed  CAS  Google Scholar 

  23. Amara SG, Jonas V, Rosenfeld MG, et al. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature. 1982;298(5871):240–4.

    Article  PubMed  CAS  Google Scholar 

  24. Wimalawansa SJ. Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev. 1996;17(5):533–85.

    PubMed  CAS  Google Scholar 

  25. Tajti J, Uddman R, Moller S, et al. Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst. 1999;76(2–3):176–83.

    Article  PubMed  CAS  Google Scholar 

  26. Eftekhari S, Salvatore CA, Calamari A, et al. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience. 2010;169(2):683–96.

    Article  PubMed  CAS  Google Scholar 

  27. Edvinsson L, Gulbenkian S, Barroso CP, et al. Innervation of the human middle meningeal artery: immunohistochemistry, ultrastructure, and role of endothelium for vasomotility. Peptides. 1998;19(7):1213–25.

    Article  PubMed  CAS  Google Scholar 

  28. Hokfelt T, Arvidsson U, Ceccatelli S, et al. Calcitonin gene-related peptide in the brain, spinal cord, and some peripheral systems. Ann N Y Acad Sci. 1992;657:119–34.

    Article  PubMed  CAS  Google Scholar 

  29. van Rossum D, Hanisch UK, Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev. 1997;21(5):649–78.

    Article  PubMed  Google Scholar 

  30. Limmroth V, Katsarava Z, Liedert B, et al. An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system. Pain. 2001;92(1–2):101–6.

    Article  PubMed  CAS  Google Scholar 

  31. Offenhauser N, Zinck T, Hoffmann J, et al. CGRP release and c-fos expression within trigeminal nucleus caudalis of the rat following glyceryltrinitrate infusion. Cephalalgia. 2005;25(3):225–36.

    Article  PubMed  CAS  Google Scholar 

  32. Storer RJ, Akerman S, Goadsby PJ. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol. 2004;142(7):1171–81.

    Article  PubMed  CAS  Google Scholar 

  33. Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med. 2007;13(1):39–44.

    Article  PubMed  CAS  Google Scholar 

  34. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33(1):48–56.

    Article  PubMed  CAS  Google Scholar 

  35. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28(2):183–7.

    Article  PubMed  CAS  Google Scholar 

  36. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23(2):193–6.

    Article  PubMed  CAS  Google Scholar 

  37. Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia. 2002;22(1):54–61.

    Article  PubMed  CAS  Google Scholar 

  38. Olesen J, Thomsen LL, Iversen H. Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol Sci. 1994;15(5):149–53.

    Article  PubMed  CAS  Google Scholar 

  39. Aiyar N, Rand K, Elshourbagy NA, et al. A cDNA encoding the calcitonin gene-related peptide type 1 receptor. J Biol Chem. 1996;271(19):11325–9.

    Article  PubMed  CAS  Google Scholar 

  40. McLatchie LM, Fraser NJ, Main MJ, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998;393(6683):333–9.

    Article  PubMed  CAS  Google Scholar 

  41. Ma W, Chabot JG, Powell KJ, et al. Localization and modulation of calcitonin gene-related peptide-receptor component protein-immunoreactive cells in the rat central and peripheral nervous systems. Neuroscience. 2003;120(3):677–94.

    Article  PubMed  CAS  Google Scholar 

  42. Eftekhari S, Edvinsson L. Possible sites of action of the new calcitonin gene-related peptide receptor antagonists. Ther Adv Neurol Disord. 2010;3(6):369–78.

    Article  PubMed  CAS  Google Scholar 

  43. Oliver KR, Wainwright A, Edvinsson L, et al. Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature. J Cereb Blood Flow Metab. 2002;22(5):620–9.

    Article  PubMed  CAS  Google Scholar 

  44. Lennerz JK, Ruhle V, Ceppa EP, et al. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol. 2008;507(3):1277–99.

    Article  PubMed  CAS  Google Scholar 

  45. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22(8):633–58.

    Article  PubMed  CAS  Google Scholar 

  46. Connor KM, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 2009;73(12):970–977.

    Article  PubMed  CAS  Google Scholar 

  47. Edvinsson L, Ho TW. CGRP receptor antagonism and migraine. Neurotherapeutics. 2010;7(2):164–75.

    Article  PubMed  CAS  Google Scholar 

  48. Sur C, Hargreaves R, Bell I, et al. CSF levels and binding pattern of novel CGRP receptor antagonists in rhesus monkey and human central nervous system: toward the development of a PET tracer. Cephalalgia. 2009;29 Suppl 1:136–7. Abstract PO326.

    Google Scholar 

  49. Ho AP, Dahlof CG, Silberstein SD, et al. Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia 2010;30(12):1443–1457.

    Article  PubMed  Google Scholar 

  50. Ho TW, Olesen J, Dodick DW, et al. Antimigraine efficacy of telcagepant based on patient's historical triptan response. Headache 2011;51(1):64–72.

    Article  PubMed  Google Scholar 

  51. Ho T, Connor K, Dahlof C, et al. Assessment of the long term safety and tolerability of telcagepant for the intermittent treatment of acute migraine: a double-blind, active-controlled study. Cephalalgia. 2009;29 Suppl 1:12. Abstract PO03.

    Google Scholar 

  52. Connor KM, Aurora SK, Loeys T, et al. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Headache. 2011;51(1):73–84.

    Article  PubMed  Google Scholar 

  53. Han TH, Blanchard RL, Palcza J, et al. Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults. J Clin Pharmacol. 2010;50(12):1367–76.

    Article  PubMed  CAS  Google Scholar 

  54. Merck, Merck Updates Status of Clinical Development Programs for Investigational CGRP Receptor Antagonist Treatments for Acute Migraine; MK-3207 Clinical Development Discontinued, Sept. 10, 2009, http://www.merck.com/newsroom/news-release-archive/research-and-development/2009_0910.html (Accessed May 10, 2011).

  55. Salvatore CA, Moore EL, Hershey JC, et al. Pharmacological characterization of MK-3207, a potent and orally bioavailable CGRP receptor anagonist. Cephalalgia. 2009;29 Suppl 1:139. Abstract PO333.

    Google Scholar 

  56. Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011;31(6):712–22.

    Article  PubMed  Google Scholar 

  57. Chan KY, Edvinsson L, Eftekhari S, et al. Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. J Pharmacol Exp Ther. 2010;334(3):746–52.

    Article  PubMed  CAS  Google Scholar 

  58. De Col R, Koulchitsky SV, Messlinger KB. Nitric oxide synthase inhibition lowers activity of neurons with meningeal input in the rat spinal trigeminal nucleus. Neuroreport. 2003;14(2):229–32.

    Article  PubMed  Google Scholar 

  59. Tassorelli C, Joseph SA. Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat. Brain Res. 1995;682(1–2):167–81.

    Article  PubMed  CAS  Google Scholar 

  60. Lambert GA, Hoskin KL, Zagami AS. Nitrergic and glutamatergic neuronal mechanisms at the trigeminovascular first-order synapse. Neuropharmacology. 2004;47(1):92–105.

    Article  PubMed  CAS  Google Scholar 

  61. Jones MG, Lever I, Bingham S, et al. Nitric oxide potentiates response of trigeminal neurones to dural or facial stimulation in the rat. Cephalalgia. 2001;21(6):643–55.

    Article  PubMed  CAS  Google Scholar 

  62. Hoskin KL, Bulmer DC, Goadsby PJ. Fos expression in the trigeminocervical complex of the cat after stimulation of the superior sagittal sinus is reduced by L-NAME. Neurosci Lett. 1999;266(3):173–6.

    Article  PubMed  CAS  Google Scholar 

  63. Akerman S, Williamson DJ, Kaube H, Goadsby PJ. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol. 2002;137(1):62–8.

    Article  PubMed  CAS  Google Scholar 

  64. Lin Q, Palecek J, Paleckova V, et al. Nitric oxide mediates the central sensitization of primate spinothalamic tract neurons. J Neurophysiol. 1999;81(3):1075–85.

    PubMed  CAS  Google Scholar 

  65. Olesen J, Iversen HK, Thomsen LL. Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. Neuroreport. 1993;4(8):1027–30.

    Article  PubMed  CAS  Google Scholar 

  66. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24 Suppl 1:9–160.

    Google Scholar 

  67. Christiansen I, Thomsen LL, Daugaard D, et al. Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. Cephalalgia. 1999;19(7):660–7.

    Article  PubMed  CAS  Google Scholar 

  68. Koulchitsky S, Fischer MJ, De Col R, et al. Biphasic response to nitric oxide of spinal trigeminal neurons with meningeal input in rat–possible implications for the pathophysiology of headaches. J Neurophysiol. 2004;92(3):1320–8.

    Article  PubMed  CAS  Google Scholar 

  69. Afridi SK, Kaube H, Goadsby PJ. Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain. 2004;110(3):675–80.

    Article  PubMed  CAS  Google Scholar 

  70. Lassen LH, Ashina M, Christiansen I, et al. Nitric oxide synthase inhibition in migraine. Lancet. 1997;349(9049):401–2.

    Article  PubMed  CAS  Google Scholar 

  71. Olesen J. Nitric Oxide-related drug targets in headache. Neurotherapeutics. 2010;7(2):183–90.

    Article  PubMed  CAS  Google Scholar 

  72. Alderton WK, Angell ADR, Craig C, et al. GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. Brit J Pharmacol. 2005;145(3):301–12.

    Article  CAS  Google Scholar 

  73. De Alba J, Clayton NM, Collins SD, et al. GW274150, a novel and highly selective inhibitor of the inducible isoform of nitric oxide synthase (NOS), shows analgesic effects in rat models of inflammatory and neuropathic pain. Pain. 2006;120(1–2):170–81.

    Article  PubMed  Google Scholar 

  74. Palmer JE, Guillard FL, Laurijssens BE, et al. A randomised, single-blind, placebo-controlled, adaptive clinical trial of GW274150, a selective iNOS inhibitor, in the treatment of acute migraine. Cephalalgia 2009;29:124.

    Google Scholar 

  75. Hoivik HO, Laurijssens BE, Harnisch LO, et al. Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia 2010;30(12):1458–67.

    Article  PubMed  Google Scholar 

  76. Høye K. LB, Harnisch LO, Twomey CK, Dixon RM, Kirkham, Williams PM, Wentz AL. Efficacy and tolerability of the iNOS inhibitor GW274150 administered up to 120 mg daily for 12 weeks in the prophylactic treatment of migraine. Cephalalgia. 2009;29:132.

    Google Scholar 

Download references

Acknowledgment

Jan Hoffmann is supported by the Deutsche Forschungsgemeinschaft (DFG) (HO4369/1-1).

Disclosure

J. Hoffmann: none. P. Goadsby: Fees for Board membership from Allergan, Colucid, MAP, MSD, Neuralieve, Neuraxon, ATI, Boston Scientific, Coherex, Eli Lilly, Medtronic, Linde Gases, BMS; Consulting fees from Pfizer and Air Products; Honoraria for speaking from MSD, Pfizer, Allergan, Mennarini.

Author information

Authors and Affiliations

  1. Department of Neurology, University of California, San Francisco, 1701 Divisadero Street, Suite 480, San Francisco, CA, 94115, USA

    Jan Hoffmann MD, PhD & Peter J. Goadsby MD, PhD

Authors
  1. Jan Hoffmann MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter J. Goadsby MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter J. Goadsby MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoffmann, J., Goadsby, P.J. New Agents for Acute Treatment of Migraine: CGRP Receptor Antagonists, iNOS Inhibitors. Curr Treat Options Neurol 14, 50–59 (2012). https://doi.org/10.1007/s11940-011-0155-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-011-0155-4

Keywords

Search

Navigation